August 09, 2026 10:13 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘A morning I will cherish’: Raghav Chadha meets PM Modi, shares photos from ‘enriching’ meeting | Delhi Mercedes crash kills 70-year-old woman: Cop’s son behind wheel, beer bottle found | Indian-origin woman accused of ‘visa fraud’ on X: US Attorney steps in with major clarification | US Senate passes Russia sanctions bill: India can face Trump’s 100% tariff threat | Expired meat, rotten vegetables found at Bengaluru's luxury hotels, legal action begins | 'I'm ready to be humiliated': Vijay, Udhayanidhi Stalin clash in Tamil Nadu Assembly over Cauvery dispute | 'They don't need Mohan Bhagwat's certificate': Priyanka Gandhi Vadra's sharp reply to RSS chief's Gen Z remark | 'Students, Gen Z, ask me anything': Rahul Gandhi launches Instagram Q&A, responds to Jharkhand protest | PM Modi goes Gen Z, urges Indians to share 'Get Ready With Me' videos on National Handloom Day | Former Tehelka editor Tarun Tejpal sentenced to 10-year jail term in 2013 rape case as Bombay HC overturns acquittal

Pharmaceuticals dept visits USP India facility in Hyderabad

| | Feb 06, 2015, at 12:26 am
Hyderabad / Kolkata, Feb 5 (IBNS): Sudhansh Pant, Joint Secretary, Department of Pharmaceuticals (DoP), visited the US Pharmacopeia's (USP) state-of-the-art India facility in Hyderabad.
He toured the facility and met with senior level scientists. The purpose of this visit was to better understand the efforts USP is making in India to create standards for medicines, ensure full safety and quality of medicines and bring to India international standards in drug manufacture. 
 
India’s continued export growth in pharmaceuticals requires that every drug exported meets with the highest quality and safety requirements. USP is uniquely positioned to provide guidelines in this area.
                        
USP develops the reference standards to ensure the quality of Active Pharmaceutical Ingredients (APIs) and is supportive of government initiatives to strengthen and revive the domestic manufacturing of intermediaries and APIs.
 
The Joint Secretary’s discussion with USP India touched upon various aspects of ensuring the quality of medicines in India and how USP standards could help Indian manufacturers to import their products both to the US and to other countries.
 
Pant also enquired about the verification program and process and showed interest in the education and training programs conducted by USP. He was very impressed by the state-of-the-art facility and appreciated the quality and safety aspects maintained in the facility.
 
KV Surendranath, Senior Vice President- International Sites Operations said, “We welcome this opportunity to showcase our technical expertise to the Department of Pharmaceuticals. We see ourselves as partners in India’s efforts to produce safe and high quality medicines that meet all global standards. We hope to continue with future engagements with the DoP on various aspects related to quality of medicines and to address issues of critical importance to patient safety.”
 
Sudhansh Pant commented that he was very impressed and that the visit was quite enlightening and informative. He noted the commendable work being done at the facility in the field of standards, testing and research and the various collaborations in the interest of the Indian pharmaceutical industry. Mr. Pant hopes that other governments and private institutions will benefit from the presence of USP’s world class facility in Hyderabad.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.